News Briefing channel feed

New Darza­lex for­mu­la­tion wins FDA ap­proval; Is­raeli biotech plans $50M IPO

6 years ago

EMA gives thumbs up to key drugs from No­var­tis, Alex­ion, Ver­tex and more

6 years ago

Ver­tex lav­ish­es $80M cash to ex­pand gene ther­a­py tool kit; Su­per­nus bags a $300M CNS port­fo­lio

6 years ago

As­traZeneca, GSK re­it­er­ate 2020 out­look; Shang­hai biotech I-Mab is look­ing for a US part­ner — re­port

6 years ago

Astel­las part­ners with In­sil­i­co, Har­vard; Zam­bon gets FDA's fast track sta­tus for lung drug

6 years ago

Re­gen­eron/Sanofi PD-1 tri­al halt­ed for sig­nif­i­cant ef­fi­ca­cy; Avadel soars on pos­i­tive nar­colep­sy da­ta

6 years ago

An up­sized IPO? In this econ­o­my? Of course; Sofinno­va and Ab­b­Vie lead $38M Se­ries A for Parkin­son’s start­up

6 years ago

EMA ap­proves Boehringer's sys­temic scle­ro­sis ther­a­py; No­var­tis' Kym­ri­ah wins RMAT sta­tus for fol­lic­u­lar lym­phoma

6 years ago

Sang­amo ties up with a new­com­er in the cell ther­a­py field; Lab­Corp wins FDA au­tho­riza­tion of lat­est Covid-19 test

6 years ago

Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

6 years ago

Gala­pa­gos finds Pol­ish part­ner for in­flam­ma­tion drugs; Zai Lab's Ze­ju­la app gets speedy re­view in Chi­na

6 years ago

Mer­ck launch­es the lat­est Her­ceptin knock­off; Har­vard spin­out grabs a $5M seed round

6 years ago

Al­ny­lam's new pipeline star gets on FDA fast track; ARCH-backed biotech nabs or­phan drug sta­tus

6 years ago

Pfiz­er nabs col­orec­tal can­cer OK for Braftovi; Bris­tol My­ers, Pfiz­er pull out of re­gion­al deal with Por­to­la

6 years ago

Keytru­da nabs an­oth­er pri­or­i­ty re­view; Quell ties up CAR pact with Han­nover Med­ical School

6 years ago

Well­come looks for back­ers of an $8B-plus Covid-19 fund; ReNeu­ron signs on an­oth­er phar­ma part­ner

6 years ago

Sue Desmond-Hell­mann joins Pfiz­er board; Kite Phar­ma taps al­ly in push to ex­pand CAR-T

6 years ago

Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

6 years ago

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

6 years ago

As­traZeneca ex­pands deal with Imag­inAb; Ovid posts promis­ing da­ta on Take­da-part­nered seizure drug

6 years ago

Oprah day in biotech: Re­ge­na­cy gets $30M, Ab­bisko gets $70M, Cas­tle Creek gets $75M

6 years ago

BEL­LUS Health buys IP rights, ban­ish­es roy­al­ties; Ab­b­Vie gets con­fir­ma­to­ry da­ta on ac­cel­er­at­ed AML drug

6 years ago

Bio­gen sues com­pa­ny al­leged­ly sell­ing ad­u­canum­ab copy­cat; J&J takes on No­var­tis' MS fran­chise

6 years ago

In­sil­i­co inks an­oth­er deal with Sino Bio­phar­ma unit; Ra­maswamy's Data­vant to in­vest in the "pa­tient jour­ney"

6 years ago
First page Previous page 41424344454647 Next page Last page
A service from the Financial Times